About this episode

This episode discusses the excitement around hair loss drugs, the impact of AI on clinical trials, and the competitive landscape of M&A in the pharma industry.

Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals.

People in this episode

Guests: Reid Waldman, David Lee

Topics covered

• hair loss drugs
• clinical trials
• M&A
• biotech
• nonprofit pharma

Keywords

• hair loss
• clinical trials
• artificial intelligence
• M&A
• biotech
• nonprofit pharma

Mentioned in this episode

Organizations: Veradermics, Servier Pharmaceuticals, Day One Biopharmaceuticals

Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.